Antibacterial phloroglucinols derivatives from the leaves of Mallotus oppositifolius (Geisler) Müll. Arg. (Euphorbiaceae)

From the ethno-medicinally used leaves of Mallotus oppositifolius, four acylphloroglucinol derivatives, namely Acronyculatin SU (1-3) and Mallotojaponin D (4) were isolated along with seven known compounds (5-11). Structures were elucidated by comprehensive spectroscopic analyses and HRMS data. Absolute configurations were assigned by careful comparison of their specific optical rotation with those of closely related compounds. Compounds 1, 2, 6 and 11 demonstrated inhibitory activity against the bacterial strains E. coli, S. aureus, S. typhi, P. aeruginosa with minimum inhibitory concentration (MIC) values ranging from 3.125 to 50 μg/ml.

Isolation and Identification of Alkaloids from Poisons of Fire Salamanders ( Salamandra salamandra)

Fire salamanders ( Salamandra salamandra) are conspicuously colored amphibians secreting a skin poison that contains unique steroid alkaloids such as samandarine (1) and samadarone (2), exhibiting toxic as well as antimicrobial activities. Because of their antipredatory and anti-infectious functions, alkaloids from Salamandra poison are of interest with regard to the threat that the lethal fungus Batrachochytrium salamandrivorans ( Bsal) poses to salamanders. Nevertheless, reliable data on the biological activity of Salamandra alkaloids are scarce, in part due to the difficulty to obtain and study those substances. Thus, isolation of pure salamander alkaloids is an important task that might directly contribute to the understanding of Bsal infections. Here we present a noninvasive isolation procedure for samandarine (1) and O-acetylsamandarine (3), as well as for two new alkaloids, O-3-hydroxybutanoylsamandarine (4) and samanone (6), using HPLC. For the first time, high-field NMR data are presented for these alkaloids. Analysis using GC/MS and ESI⁺-MS, provided important information on the structural variability of these salamander alkaloids.

Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism

Traditional therapeutic oral anticoagulation strategies often require invasive dosing or monitoring. Vitamin K antagonists (VKAs) have a large number of interactions, delayed onset requires frequent dose monitoring, and they have a small margin between therapeutic dose and bleeding complications. Novel oral anticoagulants, such as dabigatran, rivaroxaban and apixaban, are being developed to prevent those VKAs drawbacks. Besides oral bioavailability, those compounds are designed to require minimal to no monitoring and have a favourable safety profile. This review reports efficacy and safety data of these compounds throughout clinical development, as well as new approaches for oral pharmacological management of venous thromboembolism.